News FDA panel backs Ardelyx CKD drug, despite agency concerns While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having
News Hard times at Ardelyx as FDA rejects kidney disease drug ten... The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i
Views & Analysis Ardelyx’s ambition to revolutionise kidney treatment A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.
News Amid BIOSECURE Act speculation, WuXi AppTec sells unit WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.